Inside the GCC’s Healthcare Investment Transformation
GCC healthcare expenditure is projected to rise from US$109.1 billion in 2024 to US$159 billion by 2029, a compound annual growth rate of 7.8 per cent. The region is also expected to require more than 12,000 additional hospital beds over the same period. But the more important story is, where that capital is beginning to move.
Across the GCC, healthcare investment is changing shape. Hospitals, specialist centres and new clinical capacity remain important, but a growing share of strategic attention now sits around biotechnology, pharmaceutical manufacturing, genomics, artificial intelligence, clinical research, advanced surgery, digital health, longevity, long-term care, supply-chain resilience and new financing models.
The capital behind this shift is equally diverse. Governments remain major funders, but sovereign and strategic investors, private equity, venture capital, banks, multinational healthcare companies and public-private partnerships are increasingly part of the mix. In several GCC markets, policy is being designed not simply to purchase healthcare, but to attract investment, localise capability and build industries.
Click here to join our WhatsApp channel here
The clearest picture emerges when the GCC is viewed not as one healthcare market, but as six countries using different investment tools toward a similar objective.
UAE: building the health economy
At federal level, the 2026 budget allocated AED 5.7 billion to healthcare. In Dubai and Abu Dhabi, however, the direction is moving well beyond conventional service capacity toward healthtech, precision medicine, life sciences, longevity and advanced health.
Dubai made one of the year’s clearest statements with the establishment of the Dubai Longevity Authority. In September, the emirate approved the Authority’s strategy and operating budget, moving the initiative from establishment into implementation. The official announcement did not disclose the budget amount, but the policy direction is clear: longevity is being positioned as an economic and healthcare platform rather than a niche wellness category.
Dubai Health and the Dubai Future District Fund signed an MoU to develop a HealthTech and TechBio ecosystem covering biotechnology, digital health, AI diagnostics, drug discovery, robotics, medical devices and personalised medicine. The value is not only in attracting startups; it is in giving them access to clinical environments, evidence generation and routes to scale.
“The GCC healthcare investment story is no longer only about adding beds. It is increasingly about building capability.”
Genomics as infrastructure
One of the clearest examples of this change is genomics. In the UAE, genomic capability is increasingly being treated as health infrastructure rather than a standalone research programme. Reference genomes, population datasets and biobanks can support more precise diagnosis, personalised therapy, pharmacogenomics, disease-risk research and future clinical development.
A genomic platform can become an asset that attracts pharmaceutical research, precision-medicine partnerships and clinical trials. Abu Dhabi’s collaborations with global life-sciences companies increasingly draw on the emirate’s genomic and research ecosystem, showing how health data and biological infrastructure can create economic value alongside clinical value. The strategic asset is no longer only the hospital, laboratory or manufacturing plant; it can also be the trusted data, reference genome or biobank that enables discovery and more personalised care.
Saudi Arabia: scale, private capital and localisation
Saudi Arabia remains the region’s most visible healthcare transformation market by scale. Its strategy combines public investment, privatisation, PPPs, private operating models and a deliberate push to localise pharmaceutical, biotechnology and medical-technology capability.
In 2026, the Ministry of Health awarded operation of the 150-bed SABIC Mental Health Hospital in Riyadh under a public-private partnership model. A national chronic kidney disease and dialysis project is also being structured through PPP procurement and is designed to serve at least 11,500 beneficiaries. These projects show how private participation is moving into specialised care, not only general hospitals.
Also read: SSMC and National Media Authority Partner on Public Health Education
Financing architecture is becoming more sophisticated as well. A healthcare financing initiative between the Ministry of Health and the National Infrastructure Fund offers tools including co-financing and partial credit guarantees to support private healthcare projects. That moves the discussion beyond encouraging investment toward reducing the financing barriers that can delay execution.
Saudi Arabia’s direction is therefore increasingly clear: use scale to attract capital, then convert that capital into local operating, manufacturing and specialist-care capability.
Qatar: research, venture and commercialisation
Qatar’s current investment signal is less about headline hospital expansion and more about connecting its established clinical and research infrastructure with biotechnology, healthtech and venture capital.
Sidra Medicine’s MoU with Builders VC MENA illustrates this model. The partnership is designed to connect venture-backed health technologies with clinical validation while creating investment and commercialisation pathways for research emerging from Sidra itself. Hamad Medical Corporation’s collaboration with Boehringer Ingelheim similarly covers clinical research, innovation, workforce capability and health technology assessment.
Qatar Free Zones Authority’s MoU with WuXi Biologics is intended to pave the way for the company’s first integrated contract research, development and manufacturing organisation centre in the Middle East. If implemented, that would move Qatar further from being primarily a buyer of healthcare innovation toward becoming a location where innovation can be developed, validated and manufactured.
Invest Qatar has reinforced this direction through international roadshows focused on biotechnology, life sciences, healthtech and advanced technology. The country’s investment logic is increasingly about turning research capacity into commercial and investable healthcare activity.
Oman: financing local production
Oman is approaching healthcare investment through financing access, localisation and economic diversification. The Ministry of Health has signed MoUs with Development Bank and Sohar International to identify investable health projects and improve access to financing.
Development Bank had approved financing for 230 health-sector loans between 2023 and July 2026. The Sohar International framework is linked to an ambition to increase the share of locally manufactured health products from around 9 per cent to at least 30 per cent over three years. Opportunities identified by the Ministry extend beyond hospitals into medical industries, outpatient care, diagnostics, rehabilitation, long-term care and digital health. A OMR 1.5 million financing agreement was signed specifically to purchase a robotic surgery system for the Royal Hospital.
Kuwait: infrastructure and deeper private capital
Kuwait’s healthcare capital story remains heavily infrastructure-led. Major public projects continue across maternity, cancer, infectious disease and general care, while the state remains the dominant healthcare spender.
Private capital is nevertheless becoming more visible. In the medical-consumables sector, a subsidiary of Arzan Financial Group acquired 67.39 per cent of National Medical Consumable Industries, while a Sanam subsidiary acquired a further 7.61 per cent, bringing the combined ownership represented by the two transactions to 75 per cent. The transactions strengthen the private-capital story around medical manufacturing and supply.
Combined with continuing public infrastructure development and updated private-hospital frameworks, Kuwait is gradually developing a more mixed healthcare-capital model.
Bahrain: targeted capability and health-system resilience
Rather than competing through headline megaprojects alone, the market is building capability through workforce development, advanced-care partnerships, digital initiatives and medicine security.
Tamkeen and M42 are preparing to launch Amana Academy in Q4 2026, a simulation-based training centre intended initially to develop Amana Healthcare Bahrain’s workforce and later expand to specialist and allied healthcare professionals across the Kingdom. The initiative sits within a wider partnership covering training, employment, digital-health tools and healthcare innovation.
Bahrain is also active in GCC-level efforts around unified procurement, strategic pharmaceutical stockpiles and medicine security. For a smaller market, these regional mechanisms can be as economically important as an individual hospital project because they influence purchasing power, resilience and the cost base of care.
Beyond the Gulf: building for regional supply
A second trend is emerging alongside localisation: some GCC healthcare investments are being designed not only to serve domestic demand, but to supply wider regional markets. This is particularly visible in pharmaceuticals, biologics and distribution, where manufacturing scale and logistics can turn a domestic investment into a regional platform.
Saudi localisation programmes have explicitly considered export potential to GCC and wider Middle Eastern markets. Qatar’s proposed WuXi Biologics CRDMO centre similarly carries significance beyond its domestic market because contract development and manufacturing models are inherently regional and global.
The strategic logic is straightforward. Gulf markets combine strong transport connectivity, government purchasing power, free zones, capital and growing life-sciences infrastructure. As local production becomes more sophisticated, the opportunity can move from import substitution toward regional supply, research partnerships and export-oriented healthcare industries.
“In the Gulf, localisation is increasingly becoming a platform for research, manufacturing and regional supply – not simply import substitution.”
How to Read a Gulf Healthcare MoU
Not every healthcare announcement represents money already invested. In the Gulf, however, an MoU can be an important leading indicator because many localisation and market-entry projects move through several formal stages before capital is fully committed.
| Stage | What it means |
| 1. MoU / Framework | Intent to explore cooperation. A strategic signal, not yet deployed capital. |
| 2. Feasibility / Technical Work | Commercial, regulatory and operational assessment. |
| 3. Binding Agreement / JV / Financing | Ownership, funding and obligations become clearer. |
| 4. Approval / Procurement / Build | Implementation begins. |
| 5. Operations / Scale | The project becomes a functioning healthcare or commercial asset. |
For this reason, MoUs should be read as signals of direction while remaining distinct from financed projects, awarded contracts and operating assets. The value lies in understanding where the pipeline is pointing – and which announcements progress to execution.
Six markets, six investment directions
| Market | Investment direction | Signature themes |
| UAE | Build the health economy | Longevity, genomics, HealthTech, life sciences |
| Saudi Arabia | Scale and localise | Biologics, PPPs, specialist care, manufacturing |
| Qatar | Research and commercialise | Clinical trials, venture links, CRDMO |
| Oman | Finance and manufacture | Health-industry financing, localisation, pharma |
| Kuwait | Expand and deepen private capital | Hospitals, provider investment, medical manufacturing |
| Bahrain | Build targeted capability | Workforce, advanced care, biotech and digital partnerships |
Where capital is heading next
Taken together, the GCC’s healthcare investment landscape is becoming more strategic and more differentiated. Saudi Arabia is using scale, PPPs and localisation. The UAE is building a health economy around life sciences, longevity, genomics and technology. Qatar is connecting research infrastructure to venture capital and commercialisation. Oman is widening financing access while building local production. Kuwait is combining large public infrastructure with deeper private capital. Bahrain is concentrating on targeted capability, workforce and system resilience.
The common denominator is that healthcare is increasingly being treated as both a social priority and an economic sector. Governments want better outcomes and stronger resilience, but they also want intellectual property, skilled jobs, advanced manufacturing, research, investment flows and companies capable of operating beyond the domestic market.
For investors, that broadens the opportunity set. A hospital remains an investable asset, but so can a clinical-research platform, a pharmaceutical plant, a long-term-care operator, a genomic service, an AI diagnostic company, a specialist training centre or the infrastructure that connects them.
The GCC is not simply spending more on healthcare. It is redefining what healthcare investment means and increasingly using capital to build capability that can endure, scale and contribute to the wider regional economy.
“The GCC is not simply spending more on healthcare. It is redefining what healthcare investment means.”
What to Watch in the Next 12 Months
| Market | Indicator |
| Saudi Arabia | Whether the Jamjoom Pharma-Lifera biologics venture progresses from its binding structure into facility development. |
| UAE | How quickly the Dubai Longevity Authority’s MVP programme progresses into licensed activity and market-facing initiatives. |
| Qatar | Whether the proposed WuXi Biologics CRDMO centre progresses from MoU toward a binding agreement and defined implementation. |
| Oman | Whether local health-product manufacturing begins measurable progress from the current 9% share toward the 30% three-year target. |
| GCC-wide | How joint procurement develops its role in medicine security, pricing and regional supply resilience. |
